Recently, North China Pharmaceutical Company.Ltd(600812) has attracted public attention. On the one hand, its net profit attributable to the parent company in 2021 is expected to decrease by about 79.45% year-on-year; At the same time, the company’s involvement in new tea has also become a hot topic in the market.
On January 18, North China Pharmaceutical Company.Ltd(600812) staff responded exclusively to the reporter of Securities Daily: “the decline of the company’s performance is mainly affected by the epidemic situation and the reduction of government subsidies. Cross border tea is a beneficial attempt to cultivate Chinese medicine healthy consumer goods, hoping to build a new benchmark in the national tide beverage industry.”
centralized purchase qualification
is expected to recover in the second half of the year
On January 15, North China Pharmaceutical Company.Ltd(600812) announced that the company expects to realize a net profit attributable to shareholders of listed companies of about 20 million yuan in 2021, a decrease of about 77.32 million yuan or 79.45% compared with the same period of last year (statutory disclosure data); It is estimated that the non net profit attributable to the parent company is about – 59 million yuan.
For the reasons for the pre reduction of performance, North China Pharmaceutical Company.Ltd(600812) said in the announcement that this is “due to the impact of covid-19 epidemic in Gaocheng District, Shijiazhuang and the complex situation of superposition of multiple internal and external adverse factors”.
In addition, North China Pharmaceutical Company.Ltd(600812) said that compared with the same period of last year, the total non recurring profit and loss items such as government subsidies included in the current profit and loss decreased by about 80 million yuan, mainly due to the receipt of 79.44 million yuan of stabilization funds in the same period of last year.
In 2021, North China Pharmaceutical Company.Ltd(600812) also attracted much attention due to centralized mining and supply interruption. Due to the interruption of centralized procurement and supply, North China Pharmaceutical Company.Ltd(600812) was disqualified from participating in the declaration of centralized drug procurement activities organized by the state from August 11, 2021 to May 10, 2022.
Shi lichen, general manager of Dingchen pharmaceutical management consulting, said, “Centralized purchase and supply interruption event” pair North China Pharmaceutical Company.Ltd(600812) It has a great impact. The company’s related products can no longer participate in the national centralized purchase declaration for nearly 10 months, which means that it can not be sold in public medical institutions for a long time, and can only obtain some non centralized purchase revenue from the off-site market, resulting in the impact on the performance of the two financial years. It is estimated that the company can resume its participation in national centralized mining in the second half of 2022, but the impact of centralized mining and supply interruption is still difficult to eliminate after May 10, 2022. “
It is worth mentioning that, North China Pharmaceutical Company.Ltd(600812) staff told reporters, “at present, the monthly production capacity of North China Pharmaceutical Company.Ltd(600812) ibuprofen sustained-release capsules has reached 11 million, which can ensure the normal supply of centralized collection.”
aim at the tea track
looking for new performance growth points
In addition to performance, North China Pharmaceutical Company.Ltd(600812) cross-border involvement in new tea has also attracted much attention. In August 2021, North China Pharmaceutical Company.Ltd(600812) Hebei Huawei Health Industry Co., Ltd., 51% owned by North China Pharmaceutical Company.Ltd(600812) , launched the milk tea brand “Zhen Yinzi”, which was interpreted by the market as North China Pharmaceutical Company.Ltd(600812) looking for new performance growth points. However, the industry also holds different views on its cross-border tea.
Shi lichen said, “mainly due to the policy of the pharmaceutical industry, pharmaceutical enterprises are now arranging non pharmaceutical fields, such as entering daily necessities and making medical and American products to expand new business units and make up for the pressure of main business operation. North China Pharmaceutical Company.Ltd(600812) there has been great business pressure in recent years. It is estimated that getting involved in the beverage industry is caused by business pressure, especially after being suspended from the qualification of centralized purchase application.”
Hu Qimu, chief researcher of Sinosteel Economic Research Institute, said in an interview with Securities Daily: “China’s current tea has a market of 100 billion yuan, with an annual growth rate of more than 20%, North China Pharmaceutical Company.Ltd(600812) Obviously, we want to seize young consumers, give full play to the R & D advantages of pharmaceutical enterprises, make a breakthrough in healthy health tea and provide consumers with health products and services. But after all, this is a cross-border operation. There are great differences in the market characteristics of medicine and tea, and the competition in the tea market is fierce. There is uncertainty whether North China Pharmaceutical Company.Ltd(600812) ‘s brand can flourish in the new track. “
Pan Helin, executive director of the Digital Economy Research Institute of Central South University of economics and law, said: “I’m not optimistic about North China Pharmaceutical Company.Ltd(600812) cross-border beverage making, North China Pharmaceutical Company.Ltd(600812) crossing from a barrier pharmaceutical industry to a field with lower barriers, giving up my specialty and entering a strange field. This is not desirable.”
However, according to Meng Lilian, chief expert of Sichuan Tianfu Health Industry Research Institute, ” North China Pharmaceutical Company.Ltd(600812) has the capabilities and advantages that ordinary beverage enterprises do not have. However, this is only one of the necessary conditions for successful cross-border. In fact, there is a lot of room for the development of healthy food and beverage market. For example, there are many food and beverage with health as a gimmick, but there are few really healthy food and beverage. Therefore, we look forward to North China Pharmaceutical Company.Ltd(600812) cross-border.”
pharmaceutical enterprises have crossed the border
How fragrant is the new tea?
In fact, not only North China Pharmaceutical Company.Ltd(600812) , but also the time-honored brand Beijing Tongrentang Co.Ltd(600085) has become popular for selling coffee and milk tea. Its “Zhima health” offline experience store sells liquorice latte, cinnamon cappuccino, Runfei tea, black medlar grapefruit and other drinks.
How fragrant are the new tea drinks, attracting many pharmaceutical enterprises to cross the border. According to the consulting data of burning knowledge, the market scale of China’s current tea drinks in 2020 will be 113.6 billion yuan, and the compound growth rate from 2015 to 2020 will be 21.9%. It is expected that the market scale will reach 340 billion yuan by 2025.
Shi lichen said, “Cross border entry of pharmaceutical enterprises into the beverage industry is not new, such as 999 xiahuowang of Sanjiu group, Chongqing Taiji Industry (Group) Co.Ltd(600129) Taiji water, apple vinegar series of Tianfang pharmaceutical, and” slim lady “of Harbin Pharmaceutical Group “Slimming drinks, etc. since 2010, at least 50 pharmaceutical enterprises have tried to operate the beverage business. However, so far, no real mass consumer brand has been born, and most of them have died prematurely. Huabei made has been involved in fruit juice drinks and drinking water since 2014, so it is difficult to enter the beverage industry again.”
According to Hu Qimu, “Most of the cross-border drinks of pharmaceutical enterprises choose the health beverage track, that is, they make use of some health diet treatment advantages of traditional Chinese medicine to layout the large health sector, so as to realize business diversification and share the dividends of the health consumption market. However, there are obvious differences in the operation mechanism and consumption characteristics of the pharmaceutical and beverage industries, and the channel overlap is very low. Therefore, there are few cross-border successful cases of pharmaceutical enterprises Enterprises need to further explore the common ground between the pharmaceutical and beverage industries, identify the subdivision track, and then dig deep into the vertical market and strive to make a breakthrough. “
